Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource® LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.
This activity is supported by an educational grant from Ariad Pharmaceuticals, Inc.
The treatment landscape for anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) has been shaped by the emergence of targeted therapies that have demonstrated clinical efficacy. However, many perplexing challenges in the treatment of ALK-positive NSCLC remain, including the frequent development of treatment resistance and the emergence of brain metastases. Several methods exist to detect ALK fusions, but it can be difficult for busy clinicians to select and apply the best diagnostic assays along the disease continuum. Treatment-related toxicities and determining the appropriate sequencing of therapy together present another layer of complexity in the management of these patients.
To help clinicians with the management of these challenges, this case-based satellite symposium has been developed, featuring leading experts in NSCLC management. Multiple topics will be explored, including how to best manage treatment-naïve patients, treatment approaches for patients who have relapsed, and testing considerations along the disease spectrum. In addition to panel case discussions, there will be opportunities for the audience to present questions to the faculty.
This educational program is directed toward all attendees of the Annual Meeting in Chicago, including oncologists interested in the treatment of lung cancer. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with lung cancer will be invited to participate. It will also be made available to patients with lung cancer as an educational reference material.
After successful completion of this educational activity, participants should be able to: